Loading clinical trials...

COMPLETEDPHASE3

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo.

NCT00133848•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Eligibility

Age

0 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must have primary impetigo with total lesion area being 100 square centimeters or less.
•Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures.

Exclusion Criteria

•Any signs and symptoms of systemic infection.
•Any serious underlying disease that could be imminently life threatening.

Locations (22)

GSK Investigational Site

Bangalore, India

GSK Investigational Site

Hyderabad, India

GSK Investigational Site

Rome, Lazio, Italy

GSK Investigational Site

Zapopan, Jalisco, Jalisco, Mexico

GSK Investigational Site

Mexico City, Mexico

GSK Investigational Site

Beek en Donk, Netherlands

GSK Investigational Site

Deurne, Netherlands

GSK Investigational Site

Ermelo, Netherlands

GSK Investigational Site

Gouda, Netherlands

GSK Investigational Site

Musselkanaal, Netherlands

Key Dates

Start Date

April 1, 2005

Completion Date

January 1, 2006

Last Updated

September 23, 2016

Enrollment

210

Estimated participants

Conditions

Impetigo

Interventions

SB-275833 ointment, 1%

DRUG

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

NCT02090764

Impetigo

View study

COMPLETEDPHASE4

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

NCT01126268

ImpetigoFolliculitis+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 23, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Inclusion Criteria

Exclusion Criteria

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo

The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial

Citriodiol® and Impetigo